Source comparison
PT-141 Kisspeptin Protocol: Research-Grade Comparison
Primary Mechanism MC4R agonist in paraventricular nucleus → dopamine modulation in reward centres GPR54 agonist on GnRH neurons → LH/FSH pulse Same as kisspeptin-10, longer half-life in circulation Dual pathway: central arousal + hormonal activation PT-141 tar
This comparison does not assign a generated winner or score.
- Primary Mechanism
- MC4R agonist in paraventricular nucleus → dopamine modulation in reward centres
- GPR54 agonist on GnRH neurons → LH/FSH pulse
- Same as kisspeptin-10, longer half-life in circulation
- Dual pathway: central arousal + hormonal activation
- PT-141 targets arousal circuitry; kisspeptins target hormone production. Fundamentally different objectives
- Onset of Action
- 30–45 min (central effects)
- 15–30 min (LH pulse detectable)
- 20–40 min (slower due to peptide length)
- PT-141 at T-45 min, kisspeptin at T-60 min staggers peak effects
- Timing matters. Stack doses to align LH-driven testosterone rise with PT-141's dopamine peak
- Therapeutic Dose Range
- 1.0–2.0mg SC
- 0.5–2.0 µg/kg SC per pulse
- 4.0–6.4 nmol/kg IV or 1–3 µg/kg SC
- PT-141 1.5mg + kisspeptin-10 1.0 µg/kg
- Kisspeptin-54 requires IV for full effect; kisspeptin-10 is SC-viable and more practical for combined protocols
- Duration of Effect
- 6–12 hours (subjective), 2.7 hr half-life
- Single LH pulse (60–90 min), testosterone elevation 2–4 hours
- Single LH pulse, slightly longer T elevation due to peptide stability
- Overlapping 4–6 hour window of peak central + peripheral effects
- Neither peptide produces multi-day effects. Both are acute interventions
- Side Effect Profile
- Nausea (16–40%), flushing, transient hypertension
- Minimal at research doses; headache, injection site reaction
- Same as kisspeptin-10, slightly higher nausea at high IV doses
- Additive nausea risk if both dosed high; start conservatively
- PT-141's nausea is dose-dependent and unrelated to kisspeptin's mechanism. They don't compound side effects at standard doses
- Primary Research Use
- HSDD (hypoactive sexual desire disorder), arousal deficits independent of hormones
- HPG axis recovery, hypothalamic amenorrhea, fertility research
- GnRH neuron function studies, reproductive endocrinology mapping
- Multi-system arousal research: central + hormonal pathway integration
- PT-141 is FDA-approved for HSDD in women; kisspeptins remain investigational. No approved clinical formulations exist